Information about immune cell proportions and tumor stage improves the prediction of recurrence in patients with colorectal cancer.

ABSTRACT: Predicting cancer recurrence is essential to improving the clinical outcomes of patients with colorectal cancer (CRC). Although tumor stage information has been used as a guideline to predict CRC recurrence, patients with the same stage show different clinical outcomes. Therefore, there is a need to develop a method to identify additional features for CRC recurrence prediction. Here, we developed a network-integrated multiomics (NIMO) approach to select appropriate transcriptome signatures for better CRC recurrence prediction by comparing the methylation signatures of immune cells. We validated the performance of the CRC recurrence prediction based on two independent retrospective cohorts of 114 and 110 patients. Moreover, to confirm that the prediction was improved, we used both NIMO-base

SUBMITTER: Kong J 

PROVIDER: S-EPMC10318368 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature